SWOG 2408: Lanreotide vs Placebo Before Surgery to Prevent Pancreatic Fistula << Back SWOG 2408: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula IDENTIFIER ( ClinicalTrials.gov ) : NCT06807437 DRUG/TREATMENT : Lanreotide PHASE : 3 STATUS : Recruiting SPONSOR : SWOG Cancer Research Network DESCRIPTION: This is a Phase III clinical trial studying whether a medication called lanreotide can help reduce the risk of a common surgical complication in people undergoing pancreas surgery (distal pancreatectomy) for pancreatic cancer or pre-cancerous lesions. Download the Study Brochure Here What is Lanreotide? Lanreotide is a type of medication called a somatostatin analog, which is similar to a natural hormone in the body. It is already used to treat some neuroendocrine tumors (NETs) and can help control hormone levels and tumor growth. In this study, researchers are looking at whether giving lanreotide before surgery can help prevent complications. About the Study After pancreas surgery, some patients develop a complication called a pancreatic fistula, which is a leak of fluid from the pancreas that can lead to infection and other problems. This study is designed to find out: Whether lanreotide before surgery can reduce the risk of pancreatic fistulas Whether it can improve recovery, hospital stay, and quality of life How the Study Works Participants are randomly assigned (like flipping a coin) to one of two groups: Lanreotide group: receives a single injection before surgery Placebo group: receives a look-alike injection with no active drug Neither patients nor doctors will know which group they are in (a blinded study) to ensure fair and accurate results. Who Can Join This study is for adults who: Have pancreatic cancer or a pancreatic lesion Are planning to undergo distal pancreatectomy (surgical removal of part of the pancreas) What Participation Involves A single injection before surgery Standard pancreas surgery Monitoring for complications and recovery Follow-up visits and questionnaires about recovery and quality of life Why This Matters Pancreatic fistulas are a common and serious complication after pancreas surgery. If lanreotide can help reduce this risk, it could improve recovery and outcomes for patients undergoing these procedures. CONTACT For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma << Back LAMPARA: LAnreotide in Metastatic Pheochromocytoma and PARAganglioma CLINICALTRIALS.GOV IDENTIFIER: NCT03946527 DRUG/TREATMENT: Lanreotide PHASE: 2 STATUS: Recruiting SPONSOR: Antonio Fojo, Columbia University COLLABORATOR: Ipsen https://www.youtube.com/watch?v=7qaf_JDaJyM Dr. Jaydira Del Rivero Discusses LAMPARA DESCRIPTION: The objectives of this study are: To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma. To assess the toxicity and safety of lanreotide in participants with advanced or metastatic paraganglioma/ pheochromocytoma. To document the effects of lanreotide on markers of biochemical activity in participants with advanced or metastatic paraganglioma/ pheochromocytoma. Primary endpoints: Assess efficacy by estimating the tumor growth rate while a patient is enrolled on study and comparing the growth rates on lanreotide to the pre-enrolment growth rate. Secondary endpoints include measurement of: Overall survival (OS) Progression-free survival (PFS) Overall response rate (ORR) according to RECIST defined as partial response (PR) + complete response (CR) Magnitude of reduction in levels of 24-hour urinary metanephrines, catecholamines and magnitude of reduction in serum chromogranin A, evaluated every two months while enrolled on study. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here . CONTACT/Principal Investigator: Antonio Fojo, MD, PhD, Columbia University EMAIL: atf2116@cumc.columbia.edu PHONE: 212-305-9422 Research Nurse Navigator EMAIL: cancerclinicaltrials@cumc.columbia.edu PHONE: 212-342-5162

Join NCF for Dec2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page COMPREHENSIVE GUIDE TO LUNG NEUROENDOCRINE CANCERS This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoid and Atypical Carcinoid. Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. Watch the session that pertains to your diagnosis. Session A: "Typical Carcinoid & Atypical Carcinoid" https://www.youtube.com/watch?v=owZRDf3ISM4 Session B: "Large Cell Neuroendocrine Carcinoma & Small Cell Lung Cancer" https://www.youtube.com/watch?v=LxXdXMKpaCo Click here for the presentation slides from the above video. ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. 'OUR CANCER STORIES' SURVEY Researchers are currently conducting an international study approved by the NUS Ethics Committee (NUS-IRB-2023-320) to examine the relationship between emotional well-being and recovery for cancer patients. Our Cancer Stories' goal is to gather anonymous insights from individuals (aged 30-70) diagnosed with prostate and lung cancer about their personal experiences. To ensure the success of this research, they are seeking cancer patients willing to share their stories through an online survey with the option of reimbursement of $20 USD upon completion. This is a confidential, online survey that will take about 30 minutes to complete. Survey responses will be used to create stories that will be published on a website called Our Cancer Stories ( www.ourcancerstories.com ). These stories are aimed at providing readers (e.g. cancer patients, survivors, caregivers, and those with loved ones affected by cancer) with information useful in making informed decisions in fighting cancer, while providing comfort and solidarity. Take the Survey The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 46: SPOTLIGHT ON ADVANCED PRACTICE PROVIDERS (NPs & PAs) Download a Transcript of this Episode >>> ABOUT THIS EPISODE Neuroendocrine cancer care typically involves a multidisciplinary team which sometimes involves an Advanced Practice Provider (APP). In this episode, Moffitt Physician Assistant Tiffany Valone clarifies the role of an APP in neuroendocrine cancer. MEET TIFFANY VALONE Tiffany Valone is a Physician Assistant and Manager of the GI and Senior Adult Advanced Practice Providers at Moffitt Cancer Center in Tampa, FL. She started her career at Moffitt in 2006 in GI medical oncology focusing on treating patients with colorectal and pancreaticobiliary cancers. A few years into her career she joined Dr. Jonathan Strosberg to help with his growing neuroendocrine practice. For the past 16 years she has been an integral provider within this multidisciplinary team. She was awarded Moffitt’s Advanced Practice Provider of the Year in 2012 and the North American Neuroendocrine Tumor Society’s AHP/APP of the Year in 2024. She is also a member of Moffitt's APP Professional Clinical Ladder Executive Committee and spearheads Moffitt’s APP Grand Rounds lecture series. She has a passion for teaching and mentoring new providers in the NET field. She has given presentations on NETs and other GI malignancies at both state and national conferences. In her spare time, she enjoys traveling with her husband and three children or relaxing at the beach. TOP TEN QUESTIONS: What is a NP/PA/APP? Are you a doctor? How are you different from or similar to a doctor? How is your role similar to or different from a nurse practitioner? How did you enter the neuroendocrine cancer or NET world? How did you learn about neuroendocrine cancer? Could you be considered a NET expert? What is your role in the neuroendocrine cancer world? What is your role with your medical team? If I go to your institution to see a neuroendocrine cancer expert, how is it determined which provider I will see? If I see you (or another NP/PA), would I also see a doctor? If yes, when/how? If not, why/why not and how does this work? What does a “team approach” mean? Who goes over scan results? Is this something you can do? Who orders my scans and treatments? If I have a question or concern, who do I communicate with and what’s the best way to communicate? How are your recommendations communicated with someone’s local oncologist? What advice do you have for patients when they receive differing opinions? *Bonus: How do you continue to learn and keep up to date with neuroendocrine cancer? What recommendations would you have for patients who would like to encourage their local oncologists or APPs to learn about neuroendocrine cancer? DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Learn about neuroendocrine tumor surgery, including surgical options, NET liver metastases, preparing for surgery and expert patient education. Neuroendocrine Tumor Surgery Resources EDUCATIONAL WEBINARS "What Matters About Liver Surgery" with Dr. Hallet Watch here "Evolving Management of NET Liver Metastases" with Dr. Singh Watch here "Understanding Surgery for Liver NETs" with Dr. Clarke Watch here "Understanding Carcinoid Crisis" with Dr. Hallet Watch here "A Conversation with Three NET Surgeons" with Dr. Clarke, Dr. Gangi and Dr. Anaya Watch 'A Conversation with Three NET Surgeons' featuring Dr. Callisia Clarke, Dr. Alexandra Gangi and Dr. Daniel Anaya Saenz. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. Watch here "NET Surgery: Making Decisions & Preparing for Surgery" with Callisia Clarke, MD Is surgery the right treatment option for you? Dr. Callisia Clarke joined us for our annual patient conference to address surgery for NETs including decision-making & preparing for surgery. Watch here "Patient Story: How to Prepare for Surgery" NET patient Julie’s “show and tell” of tips, tricks, and specific items she found useful during her hospital stay and recovery at home. Click here for a list of the items Julie mentioned in this video. Watch here Click here for our full surgery video playlist. PODCAST EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW SURGERY FOR NETS To cut or not to cut? A crossroad many neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope answers the top 10 surgery questions for NETs. LISTEN NOW KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW ADDITIONAL SURGERY RESOURCES NET Quiz - Test Your Knowledge! How much do you really know about surgery and international radiology for NETs? Test your NET knowledge by taking this six question quiz based off of the NETWise podcast episode #3: “Surgery and Interventional Radiology for NETs.” Take the Quiz Blog Post - Practical Tips for Patients Preparing for Surgery Many NET patients undergo surgery as part of their treatment course. While their medical team might have specific preparation instructions, patients often wonder about practical concerns like how to plan, what to pack, and how to prepare the home... Read the Blogpost

Join NCF for California. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page Registration is closed. Please contact us at events@ncf.net to be added to the waitlist. ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Hear four presentations from neuroendocrine cancer experts. Engage in two Q&A sessions. Listen to a patient story. Learn about liver-directed therapy, systemic therapy, PRRT, and clinical trials. Network with other patients and caregivers. A light dinner will be served. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Alexandra Gangi (Cedar-Sinai Medical Center). This event will not be broadcast or recorded. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> LOCATION Sandbourne Santa Monica 1740 Ocean Avenue Santa Monica, CA 90401 THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 3:45 - 4:15 PM Check-in 4:15 - 4:25 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 4:25 - 4:30 PM Patient Story 4:30 - 4:45 PM Liver-Directed Therapy: Understanding Minimally Invasive Options to Treat Liver Tumors Gabriel Lipshutz, MD, Interventional Radiologist, Cedars-Sinai 4:45 - 5 PM Systemic Therapy for NETs: Medical Options for Metastatic Tumors J. Randolph Hecht, MD, UCLA 5 - 5:45 PM Q&A with Expert Panel Callisia Clarke, MD, Julie Hallet, MD, Gabriel Lipshutz, MD, Randolph Hecht, MD; Moderated by Alexandra Gangi, MD 5:45 - 6:30 PM Break & Dinner 6:30 - 6:45 PM PRRT: Current & New Trends Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic 6:45 - 7:00 PM Clinical Trials: The Latest & Greatest Heloisa Soares, MD, Huntsman Cancer Institute 7:00 - 7:30 PM Q&A with Expert Panel Thorvardur Halfdanarson, MD, Heloisa Soares, MD, Alexandra Gangi, MD; Moderated by Andrew Hendifar, MD 7:30 PM Closing Neuroendocrine Cancer Foundation Team This agenda is subject to change. Please check this page for the most updated agenda. ABOUT OUR SPEAKERS Callisia Clarke, MD, MS, FACS, FSSO Chief of MCW Surgery Medical College of Wisconsin Panelist Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Alexandra Gangi, MD Surgical Oncologist Cedars-Sinai Medical Center Moderator/Panelist Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. Thorvardur Halfdanarson, MD Medical Oncologist Mayo Clinic Speaker/Panelist Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is the President Emeritus for the North American Neuroendocrine Tumor Society (NANETS). Julie Hallet, MD, MSc., FRCSC Surgical Oncologist Sunnybrook Health Sciences Center Panelist Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet’s research focuses on health services research to improve the fidelity of care delivery in cancer surgery through patient-centred quality monitoring, high-performing team care models, and patient risk-communication support. Her work has obtained over $10 millions in peer-reviewed operating grants and led to more than 220 peer-reviewed publications. J. Randolph Hecht, MD Medical Oncologist UCLA Health Speaker/Panelist Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. Andrew Hendifar, MD Medical Oncologist Cedars-Sinai Medical Center Moderator The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. J. Gabriel Lipshutz, MD Interventional Radiologist Cedars-Sinai Medical Center Speaker/Panelist H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. Dr. Heloisa Soares Medical Oncologist Huntsman Cancer Institute Speaker/Panelist Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79.

< Back to the supporters page Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

Join NCF for Sep2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page "Practical Tips in Managing Neuroendocrine Cancer Care" https://www.youtube.com/watch?v=j9kzpBG7z94 Some Topics Covered: NET care, cancer care coordination, NET specialist, oncology appointments, patient advocacy, tumor board, second opinions, cancer scans, symptom management, palliative care, patient navigation, communicating with your doctor ABOUT Join Taymeyah and Tiffany as they share important insights to help you spearhead your medical team and confidently navigate your healthcare. Gain practical logistics for managing the ongoing cycle of scans, lab work, and "ologist" appointments. Discover well-informed, real-world suggestions on finding and building strong partnerships with your providers and specialists. We hope this discussion empowers you to effectively and efficiently coordinate your care. ABOUT TIFFANY ROMERSHAUSEN Tiffany Romershausen MPH, MSN, AGPCNP-C Advanced Practice Registered Nurse Moffitt Cancer Center, Tampa, FL Tiffany Romershausen is an Advanced Practice Registered Nurse serving Neuroendocrine Tumor (NET) patients at Moffitt Cancer Center in Tampa, FL. She has a diverse background with over 12 years of experience in direct patient care and clinical research. Tiffany has a dual bachelors from the University of South Florida in Nursing and Biomedical Sciences. In addition, she holds a Master of Science in Nursing and a Master of Science in Global Communicable Disease. Tiffany has a zeal for equipping patients with the tools to make informed decisions and is actively engaged in NET clinical trials at Moffitt. THANKS TO OUR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

Explore resources on high-grade neuroendocrine tumors & neuroendocrine carcinoma, including diagnosis, treatment options, clinical trials & patient support. Resources for High-Grade Neuroendocrine Tumors & Neuroendocrine Carcinoma CLINICAL TRIALS Learn more about clinical trials specifically for High Grade, Grade 3 (G3) Neuroendocrine Tumor (NET) and Neuroendocrine Carcinoma (NEC). Visit High Grade NET & NEC Clinical Trials Page WATCH "Targeted Therapies & Chemotherapy" with Udhayvir Grewal, MD The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan "Large Cell Neuroendocrine Carcinoma & Small Cell Lung Cancer" with Aman Chauhan, MD Click here to download the presentation slides from the above video. "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" with Aman Chauhan, MD "Updates in High Grade Neuroendocrine Neoplasms" with Jason Starr, MD "Updates in High Grade Neuroendocrine Cancers" with Aman Chauhan, MD "Focus on Immunotherapy & High-Grade NETs" with Namrata Vijayvergia, MD "The Latest on Immunotherapy for Neuroendocrine Cancer" with Rohit Thummalapalli, MD "The Latest on Immunotherapy for Neuroendocrine Cancer" with Aman Chauhan, MD Click here to download the presentation slides from the above video. LISTEN DLL3 is emerging as a promising new target for neuroendocrine cancers. In this episode, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explains what DLL3 is, how it works, who might benefit, and what current clinical trials are teaching us. He breaks down the science, treatment options, and future directions in a way that is clear, approachable, and designed to help patients and families better understand this developing area of care. Click here for the podcast, transcript and resources >> Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare and complex cancer that can be difficult to recognise, diagnose, and treat. This short video helps patients and care partners understand the disease, including what to expect from diagnosis and treatment, the urgency needed, and where support is available. It is designed to help patients and their families navigate this challenging condition. Click here for more information >>> In this video podcast by COR2ED, Neuroendocrine Patient Advocate Susan Meckler-Plummer joins Medical Oncologist Dr. Aman Chauhan to discuss extra-pulmonary neuroendocrine carcinomas (EP-NECs). Click here for more information >>> What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. Click here for the podcast, transcript and resources >> What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. Click here for the podcast, transcript and resources >> Listen to the NETWise Podcast here >> READ Patient Guide for High-Grade Neuroendocrine Cancers By HealingNET Foundation Download Here Expert Consensus Practice Recommendations of NANETS for the Management of High Grade Gastroenteropancreatic and Gynecologic Neuroendocrine Neoplasms Read Here SCHOLARLY ARTICLES: WELL DIFFERENTIATED HIGH-GRADE NETS Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors BLOG POST Practical Tips For Patients Preparing For Chemotherapy PATIENT STORY A patient living and thriving with high grade neuroendocrine cancer shares her inspiring story. FACEBOOK GROUP Join the High Grade Neuroendocrine Carcinoma FB group here. For more information & and support, contact high grade patient advocate Susan Meckler Plummer, who supported her late husband with NEC. Susan Meckler Plummer 609-731-0322 susan@netsmission.org

225Ac-ABD147 to Establish Optimal Dose in SCLC and LCNEC << Back A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy IDENTIFIER ( ClinicalTrials.gov ) : NCT06736418 DRUG/TREATMENT : 225Ac-ABD147 PHASE : 1A/B STATUS : Recruiting SPONSOR : A bdera Therapeutics Inc. https://www.youtube.com/watch?v=PDR0flgpAXE DLL-3-RLT Presentation Slides .pdf Download PDF • 863KB DESCRIPTION: This is an open-label, Phase 1a/1b, first-in-human study testing a new targeted treatment called 225Ac-ABD147 for people with locally advanced or metastatic small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung. All participants must have previously received platinum-based chemotherapy. What is 225Ac-ABD147? 225Ac-ABD147 is a DLL3-targeting antibody fragment, a small, engineered piece of an antibody that targets cancer cells with a marker called delta-like ligand 3 (DLL3) . It is attached to a special linker-chelator that holds a radioactive particle ( Actinium-225 ) so that a precise dose of radiation can be delivered directly to DLL3-positive cancer cells. The study has two parts: Phase 1a and Phase 1b . Phase 1a: Safety, Dosing & Early Signals Phase 1a is designed to understand: Safety and side effects How the drug moves through the body (PK and biodistribution) Early signs of effectiveness The safest and most appropriate dose levels A small group of participants will also receive an experimental imaging agent, 111In-ABD147 , to help researchers see how the treatment travels and where it binds in the body. Phase 1b: Expanded Testing at Selected Doses Phase 1b uses the dose levels identified in Phase 1a to further evaluate: Safety How well the treatment works for SCLC and LCNEC This phase helps researchers better understand the potential benefit of 225Ac-ABD147 in these cancers. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Abdera Therapeutics Inc. EMAIL: AbderaClinicalTrials@abderatx.com PHONE: 1 650-434-4093 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Go back to the Podcast page EPISODE 10: PRRT (PART III) Download a Transcript of this Episode >> Listen to Episode 8: PRRT (Part One) with Administrative Nurse Lindy Gardner of UCLA Health >> Listen to Episode 9: PRRT (Part Two) with the Director of Nuclear Medicine of UCLA Health >> ABOUT THIS EPISODE How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? What is the patient experience with traveling after PRRT? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT. MEET JOSH MAILMAN, MBA Josh Mailman was diagnosed with PNET in 2007. Josh is an internationally recognized advocate for NET patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging. He is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, acting COO the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), and president of NorCal CarciNET Community, one of the largest NET patient communities in the United States. In addition, he is a member of National Cancer Institute’s GI Steering Committee after being a member of the NCI Task Force on Neuroendocrine Tumors for seven years. Josh is also a member of the Board of Directors and Executive Committee of the Neuroendocrine Tumor Research Foundation(NETRF). He sits as the single patient member of NETRF's Scientific Advisory Committee which reviews research applications for private funding by this 501c3 foundation. In 2015, Josh was honored with the Warner Advocacy Award, given annually by Novartis Oncology Patient Advocacy and The NET Alliance. The award recognizes an individual for leadership and advocacy for neuroendocrine patients. In the same year, Josh was given the SNMMI’s President’s Award for his work on behalf of patients in the nuclear medicine field. Josh is a former executive board member of the Society for Integrative Oncology (SIO)and was named SIO Patient Advocate of Year in 2010. Josh is a frequent and sought-after speaker for his passionate and highly informed perspective on how patients can effectively participate in the process of working with key stakeholders to improve treatments and advance progress for better quality of life and eventual cures. TOP 10 PRRT QUESTIONS 1. PRRT was available for years outside the USA before it was available here. Why did it take so long before PRRT was available in the US? 2. How does PRRT differ in the USA versus in Europe and other parts of the world? 3. Why is PRRT so much more expensive in the US vs other places in the world? Is it covered by insurance / for lung NETS? 4. Now that Lutathera is more widely available, how does one go about deciding where to get treatment? (Does it matter if I get it locally vs a “NET center?”) / Does it matter where you go to receive your PRRT treatment? (Do I need to be going to a NET center to receive PRRT treatment?) 5. Some people are told they can only receive 4 doses of PRRT in their lifetime. What are your thoughts about this? Do we always need 4 treatments? / How might patients decide when to have repeat PRRT versus having another type of PRRT or another treatment? What might you need to consider as a patient and advocate? 6. What is the patient experience regarding traveling after PRRT? (Do I need to worry about setting off security alarms at airports? What about other security alarms such as at event venues or courthouses?) 7. How might patients go about deciding between various PRRT options (i.e. alpha versus beta)? What might you consider as a patient and as an advocate? 8. Some people are told that PRRT should be saved as a “last resort.” How would you respond? 9. What is your role as a member of the Nuclear Regulatory Commission’s Advisory Committee on the Medical Use of Isotope? 10. Talk a little bit about the release criteria and radiation safety precautions following Lutathera. Why is there a range of what patients are told? How does the process & procedure of radiation safety in the USA differ in the USA vs Europe and other parts of the world? ADDITIONAL RESOURCES Read the LACNETS Blog Post "These Four Letters: PRRT" >> Click here for additional PRRT Resources >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Back Carcinoid Syndrome CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine in Carcinoid Syndrome